Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Valeant Pharmaceuticals Reports Encouraging Final Results With Taribavirin Phase IIb Study
Valeant Pharmaceuticals International (NYSE: VRX) reported final results for its Phase IIb dose-finding clinical trial for taribavirin, a prodrug of ribavirin which is in development for the treatment of chronic hepatitis C in conjunction with a pegylated interferon. The study in treatment naive genotype 1 infected subjects was of standard design, consisting of 48 weeks of treatment with a 24-week follow-up period. It explored three weight-based doses of taribavirin: 20 mg/kg, 25 mg/kg and 30 mg/kg vs. ribavirin 800-1400 mg/day. Throughout the 72-week trial, all doses of taribavirin demonstrated comparable efficacy (sustained virologic response (SVR)) to ribavirin with consistently lower levels of anemia. In addition, relapse rates in the 25 mg/kg and 30 mg/kg arms were comparable with the ribavirin arm; supporting the premise that higher dose weight-based taribavirin may be as effective as weight based ribavirin. Valeant plans to present the full final data at the American Association for the Study of Liver Disease (AASLD) later this year.

SonoSite Introduces Innovative Delivery Of Ultrasound Education Using IPhone™ Application
SonoSite, Inc. (Nasdaq:SONO), the world leader and specialist in hand-carried ultrasound for point-of-care medicine, announced today the launch of the SonoAccess™ application, the first medical iPhone app from an ultrasound company that provides a multimedia library of ultrasound re materials for medical professionals to access when and where they need it.
News of the day
Obama's Embryonic Stem Cell Proposal Goes 'Only Halfway' To Improving Research, Columnist Says
The Obama administration"s draft guidelines outlining criteria for federal funding of stem cell research "go only halfway toward freeing embryonic stem cell research" because "[s]ome of the most promising investigations will still be denied federal funding," syndicated columnist Froma Harrop writes in a Providence Journal opinion piece. Harrop writes that although "the public supports the research by more than two to one," there is "a vocal minority opposed to this work because it requires the destruction of embryos." According to Harrop, although Obama allowed research on embryos willingly donated by fertility clinic patients and lifted former President George W. Bush"s restrictions limiting federal funding to research on 21 existing stem cell lines, he "wouldn"t budge on the prohibition against funding research that allows for the creation of embryos out of human cells," known as therapeutic cloning. She notes that "therapeutic cloning has little to do with human cloning, which is about making new people and is illegal most everywhere. But say that cloning is being used in research, and many folks think they"re going to have a clone as a neighbor in a few years."Harrop continues, "[B]y allowing the use of embryos from fertility clinics and not those created by researchers, the administration lends credence to the view that embryos are full human beings." However, the "only difference between embryos in fertility clinics and the ones cloned for research is the motive of the people who created them." She concludes, "Obama"s timidity in rewriting the guidelines has slowed down important research and produced more confusion. And for Americans praying for cures from this science, the choice seems rather clear" (Harrop, Providence Journal, 5/28).
Cardiovascular

Growing Midwestern Clinical Research Organization Selects OmniComm Systems To Provide EClinical Solutions For Phase IV Studies

OmniComm Systems, Inc. (OTC Bulletin Board: OMCM), a leader in integrated electronic data capture (EDC) solutions for clinical trials announced that a growing US Clinical Research Organization (CRO) has selected OmniComm to provide eClinical solutions in connection with two of the CRO"s Phase IV studies covering approximately 27 sites and more than 700 subjects. Additional details were not disclosed. Phase IV studies take place after a drug has been approved for marketing and are designed to provide broader experience in evaluating the safety and effectiveness of the new medicine in larger numbers of patients, subpopulations of patients, and to compare and/or combine it with other available treatments. "We are pleased to have been selected by this CRO to provide eClinical solutions for these important Phase IV studies," said Cornelis F. Wit, OmniComm"s President and CEO. "We believe the broad scope of our integrated eClinical solutions, enhanced by the recent acquisition of eResearch Technology"s data capture unit, positions us well to offer a broad array of solutions, especially for CRO"s, pharmaceutical, biotech and medical device companies seeking cost-effective tools to capture and track outcomes of clinical trials conducted at multiple locations. We look forward to expanding the range of services we provide for companies seeking to increase efficiencies in their clinical activities." About OmniComm OmniComm Systems, Inc. provides customer-driven Internet solutions to pharmaceutical, biotechnology, research and medical device organizations that conduct life changing clinical trial research. OmniComm"s growing base of satisfied customers is a direct result of the company"s commitment to deliver products and services that ensure ease of use, faster study build, ease of integration and better performance. OmniComm"s client intuitive pricing model allows companies that range from small, to mid-size to large scale institutions to safely and efficiently capitalize on their clinical research investments. OmniComm Systems, Inc. has corporate headquarters in Ft. Lauderdale, Florida and offices in Bonn, Germany, Tula, Russia, California, Connecticut, Georgia, Illinois, New Jersey, New York, North Carolina and Tennessee. Safe Harbor Disclaimer Statements made by OmniComm included in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties such as the Company"s ability to obtain new contracts and accurately estimate net revenues due to uncertain regulatory guidance, variability in size, scope and duration of projects, and internal issues at the sponsoring client, integration of acquisitions, competitive factors, technological development, and market demand. As a result, actual results may differ materially from any financial outlooks stated herein. Further information on potential factors that could affect the Company"s financial results can be found in the Company"s Reports on Form 10-K and 10-Q filed with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. OmniComm Systems, Inc


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009